Global pharmaceutical giant Jazz Pharmaceuticals has filed a lawsuit alleging that a series of generic drug companies have infringed on its patent for Epidiolex, a cannabis-derived drug used to treat seizures in Dravet syndrome, tuberous sclerosis and Lennox-Gastaut syndrome. The lawsuit, filed in New Jersey federal court, alleges that Alkem, Apotex, Teva Pharmaceuticals and other generic drug makers submitted plans to sell generic variants of Epidiolex to the U.S. Food and Drug Administration, according to financial media agency Benzinga. Ireland-based Jazz claims its patent, registered by a subsidiary of GW Pharmaceuticals, protects "the composition and method of use of Epidiolex and the method of treatment using Epidiolex" until 2035 and beyond. According to the pharmaceutical blog Fierce Pharma, the generic drug maker says the generics do not infringe the patents, which Jazz acquired when it bought U.K.-based GW Pharmaceuticals for $7.2 billion in 2021.
Information source: new.qq.com/omn/author/8713560